GLP-1 receptor agonists bind to GLP-1R on pancreatic beta cells and extrapancreatic tissues, enhancing glucose-dependent insulin secretion and modulating central appetite regulation through vagal afferent signaling. This mechanism engages the nutrient-sensing mTOR and AMPK pathways, attenuating hyperinsulinemia and activating cellular stress-response programs implicated in aging. Preclinical models demonstrate lifespan extension through reduced metabolic disease burden and improved mitochondrial autophagy, while human evidence from cardiovascular outcome trials shows 15-20% reduction in major adverse events and 4% all-cause mortality reduction in type 2 diabetes cohorts. The proposed healthspan benefit derives from simultaneous improvements in glucose homeostasis, body composition, and systemic inflammation, though human lifespan data remain absent.
Yes. GLP-1 receptor agonists are FDA-approved for type 2 diabetes and, in several formulations, for chronic weight management. Cardiovascular and longevity-adjacent benefits are an active area of evidence beyond these core approvals.
The SELECT trial (2023) reported a pooled hazard ratio of 0.80 (95% CI 0.72–0.90) for major adverse cardiovascular events (MACE), among the strongest outcome-level evidence tracked across any intervention on Geroevidence.
This tier reflects Phase III RCT evidence with a hard cardiovascular outcome (MACE) rather than a surrogate endpoint, consistent with Geroevidence's four-tier grading methodology described on the Intervention Index page.
Gastrointestinal effects (nausea, vomiting) are the most commonly reported. Rare but serious risks identified in approved indications include pancreatitis and gallbladder disease; long-term safety data continues to accumulate.
Both are graded Strong. GLP-1 agonists show HR 0.80 for MACE (SELECT 2023); SGLT2 inhibitors show HR 0.62 for cardiovascular death (EMPA-REG 2015). See the SGLT2 inhibitors profile for direct comparison.